A Study of Risvutatug Rezetecan in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) [EMBOLD Prostate-302]

This study aims to evaluate how well risvutatug rezetecan (Ris-Rez) works in treating prostate cancer compared to best supportive/standard of care (BSC) which may include a hormone therapy with an androgen receptor pathway inhibitors (ARPI), by checking whether it makes cancers smaller or disappear completely, if it helps participants live longer, and/or feel better. The study is also assessing whether Ris-Rez is safe and tolerated well by participants and aims to provide a better understanding of the side effects of the drug.

Trial Details

NCT ID
NCT07802704
Phase
PHASE3
Sponsor
GlaxoSmithKline
Status
RECRUITING
Cancer Type
Prostate Cancer
Interventions
  • Risvutatug rezetecan (Ris-Rez)
  • Enzalutamide
  • Abiraterone
  • Prednisone
  • Prednisolone
Locations (sample)
  • Auchenflower, Queensland, Australia|-27.47443,152.99213
  • Montreal, Quebec, Canada|45.50884,-73.58781
  • Tokyo, Japan|35.6895,139.69171
  • Tottori, Japan|34.24877,134.67796
  • Seoul, Seoul Teugbyeolsi, South Korea|37.566,126.9784

Key Eligibility Criteria

  • Participants ≥18 years of age
  • Has histologically or cytologically confirmed adenocarcinoma of the prostate.
  • Has an Eastern Cooperative Oncology Group (ECOG) PS of 0 or 1, with no deterioration in the 2 weeks before randomization.
  • Has a life expectancy of at least 4 months.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Prostate Cancer Trials on Trialify →